PT1901773E - Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos - Google Patents

Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos Download PDF

Info

Publication number
PT1901773E
PT1901773E PT06754207T PT06754207T PT1901773E PT 1901773 E PT1901773 E PT 1901773E PT 06754207 T PT06754207 T PT 06754207T PT 06754207 T PT06754207 T PT 06754207T PT 1901773 E PT1901773 E PT 1901773E
Authority
PT
Portugal
Prior art keywords
ides
pyogenes
proteinase
autoimmune diseases
graft rejection
Prior art date
Application number
PT06754207T
Other languages
English (en)
Portuguese (pt)
Inventor
Rikard Holmdahl
Lars Bjorck
Kutty Selva Nandakumar
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of PT1901773E publication Critical patent/PT1901773E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT06754207T 2005-06-09 2006-06-08 Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos PT1901773E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment

Publications (1)

Publication Number Publication Date
PT1901773E true PT1901773E (pt) 2012-06-06

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06754207T PT1901773E (pt) 2005-06-09 2006-06-08 Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos

Country Status (14)

Country Link
US (1) US8133483B2 (cg-RX-API-DMAC7.html)
EP (1) EP1901773B1 (cg-RX-API-DMAC7.html)
JP (1) JP5427409B2 (cg-RX-API-DMAC7.html)
CN (1) CN105770871A (cg-RX-API-DMAC7.html)
AT (1) ATE548049T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006256891B2 (cg-RX-API-DMAC7.html)
BE (1) BE2021C505I2 (cg-RX-API-DMAC7.html)
CA (1) CA2611646C (cg-RX-API-DMAC7.html)
ES (1) ES2380950T3 (cg-RX-API-DMAC7.html)
FR (1) FR21C1004I2 (cg-RX-API-DMAC7.html)
NL (1) NL301089I2 (cg-RX-API-DMAC7.html)
PL (1) PL1901773T3 (cg-RX-API-DMAC7.html)
PT (1) PT1901773E (cg-RX-API-DMAC7.html)
WO (1) WO2006131347A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216863B8 (en) * 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
US8691544B2 (en) 2007-05-04 2014-04-08 Glycorex Transplantation Ab Material for separation of a biomolecule
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
ES2535963T3 (es) 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
US8673606B2 (en) * 2009-04-22 2014-03-18 Ofir Menashe Microorganism comprising particles and uses of same
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
SG11201806639VA (en) 2016-02-04 2018-09-27 Genovis Ab New streptococcal proteases
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP7668261B2 (ja) * 2019-08-01 2025-04-24 メモリアル スローン ケタリング キャンサー センター 改良された免疫療法のための細胞およびその使用
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
JP2023541698A (ja) * 2020-09-21 2023-10-03 上海宝済薬業有限公司 組合せ医薬及びその使用
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
JP2024547125A (ja) * 2021-12-22 2024-12-26 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
KR20250123949A (ko) 2022-11-18 2025-08-18 사이즈믹 테라퓨틱, 인코포레이티드. Fc 융합 분자 및 이의 용도
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261585B2 (en) * 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
PL1901773T3 (pl) 2012-09-28
US8133483B2 (en) 2012-03-13
EP1901773B1 (en) 2012-03-07
FR21C1004I1 (cg-RX-API-DMAC7.html) 2021-03-26
WO2006131347A3 (en) 2007-05-31
CN105770871A (zh) 2016-07-20
JP5427409B2 (ja) 2014-02-26
FR21C1004I2 (fr) 2022-01-14
EP1901773A2 (en) 2008-03-26
US20100303781A1 (en) 2010-12-02
BE2021C505I2 (cg-RX-API-DMAC7.html) 2021-05-31
NL301089I2 (nl) 2021-02-04
ES2380950T3 (es) 2012-05-21
WO2006131347A2 (en) 2006-12-14
JP2008542418A (ja) 2008-11-27
AU2006256891B2 (en) 2011-08-04
CA2611646C (en) 2015-08-11
ATE548049T1 (de) 2012-03-15
NL301089I1 (cg-RX-API-DMAC7.html) 2021-01-20
AU2006256891A1 (en) 2006-12-14
CA2611646A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
FR21C1004I2 (fr) Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
MXPA05012718A (es) Anticuerpos humanizados que reconocen el peptido beta amiloide.
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
TW200636066A (en) Humanized antibodies that recognize beta amyloid peptide
WO2003048327A3 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200738270A (en) Method of treating depression using a TNFα antibody
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
JO2576B1 (en) Antibodies
TW200740844A (en) Novel MAdCAM antibodies
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2005072223A3 (en) Engineered proteins, and methods of making and using
WO2007135571A3 (en) Blood group antigens of different types for diagnostic and therapeutic applications
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
WO2007068750A3 (en) Immunoglobulins directed against nogo
SG170804A1 (en) Pseudomonas aeruginosa outer membrane protein pa0427
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
WO2005071067A3 (en) Non-animal origin stabilizers and processes for producing the same
IL169367A0 (en) Defensin proteins
WO2004074436A3 (en) Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
WO2007101988A3 (en) Use of tsg-6 for treating bone diseases
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения